<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072631</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-774-202</org_study_id>
    <secondary_id>Dose to Rash</secondary_id>
    <nct_id>NCT00072631</nct_id>
  </id_info>
  <brief_title>Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if erlotinib will improve disease at doses that
      produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only patients with 0 to 1 performance status on the ECOG scale are eligible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2003</start_date>
  <completion_date type="Actual">March 14, 2007</completion_date>
  <primary_completion_date type="Actual">March 14, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of intrapatient dose escalation of erlotinib HCI to introduce a characteristic, target rash, and evaluate the effect on objective response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of correlating objective response rate and duration of response to grade of rash</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <condition>Failed Prior Chemotherapy</condition>
  <arm_group>
    <arm_group_label>1 erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva (Trademark) (erlotinib HCl, OSI-774)</intervention_name>
    <description>Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash</description>
    <arm_group_label>1 erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or
             cytological).

          -  Received prior chemotherapy treatment for advanced, metastatic non-small cell lung
             cancer.

          -  Measurable disease per RECIST criteria.

          -  Adequate bone marrow, hepatic and renal function.

        Exclusion Criteria:

          -  Breast cancer or skin cancer at any time in the past or any other cancer in the past 5
             years.

          -  Brain metastases that are unstable, require steroids, are life-threatening or required
             radiation in the last 28 days.

          -  Known hypersensitivity to minocycline.

          -  History of serious cardiac disease that is not controlled.

          -  Serious eye conditions.

          -  Prior treatment with inhibitors of EGFR of any kind.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Drug Development Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=56</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2003</study_first_submitted>
  <study_first_submitted_qc>November 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2003</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tarceva</keyword>
  <keyword>erlotinib</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>EGFR</keyword>
  <keyword>OSI-774</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

